&w=3840&q=100)
Zydus signs deal with Agenus for BOT and BAL cancer therapies in India
Zydus Lifesciences Limited has signed a definitive agreement with Agenus Inc. to acquire commercial rights for India and Sri Lanka for the investigational combination therapy Botensilimab (BOT) and Balstilimab (BAL).
Agenus is a clinical-stage immuno-oncology company focused on developing immune therapies for the treatment of cancer.
'Our licensing partnership with Agenus aligns with Zydus' overarching biologics vision and our aim to advance novel solutions for high-unmet need areas,' said Dr Sharvil Patel, Managing Director of Zydus Lifesciences.
The BOT and BAL combination is a next-generation immunotherapy platform aimed at enhancing and sustaining the immune system's ability to respond to tumour cells.
BOT is an investigational anti-CTLA-4 antibody designed to activate immune cells and generate durable immune responses. BAL is an investigational anti-PD-1 antibody that blocks the PD-1 pathway, thereby supporting T cell activity against cancer cells.
This combination is currently in advanced clinical trials and has shown clinical activity in more than 1,200 patients across nine types of cancer, including colorectal cancer, melanoma, lung cancer, ovarian cancer, gastric cancer, pancreatic cancer and non-small cell lung cancer. The trials cover both late-stage and neoadjuvant (pre-surgery) treatment settings.
Under the terms of the agreement, Zydus will be responsible for clinical development and regulatory approvals of the licensed products in India and Sri Lanka. Upon successful approval and commercialisation, Zydus will pay a 5 per cent royalty on net sales.
'Agenus' robust pipeline and research in immuno-oncology, along with Zydus' reach as the largest Indian oncology player, mark a significant step forward in our collective fight against cancer. We are confident that this collaboration will bring transformative therapies to patients who need them most in the India and Sri Lanka markets,' Dr Patel added.
Zydus also stated its intention to broaden the use of the BOT and BAL combination therapy beyond current indications. The company aims to expand into other high-unmet-need indications, earlier lines of treatment, and additional neoadjuvant applications.
CDMO agreement
In a parallel development, Zydus Lifesciences announced its entry into the global biologics contract development and manufacturing organization (CDMO) sector through an agreement to acquire the biologics CMC facilities of Nasdaq-listed Agenus Inc. in the United States.
As part of the CDMO agreement, Zydus will purchase two biologics manufacturing sites located in Emeryville and Berkeley, California, for an upfront payment of $75 million. An additional $50 million will be paid over a period of three years, contingent on the achievement of specified revenue milestones.
Market.us estimates the global biologics CDMO market will reach approximately $84.9 billion by 2034, with a compound annual growth rate of 15.7 per cent from 2025 to 2034.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mint
12 minutes ago
- Mint
Anil Ambani-owned Reliance Infrastructure share price dips 5% after THIS reply on 155mm artillery shells
Anil Ambani-owned Reliance Infrastructure's stock took a breather on Thursday after a sharp 11% gain in the last trading session, with the scrip declining 5% in intra-day deals today. Apart from profit taking following a sharp rally in recent months, Reliance Infra share price also came under pressure following its response to the exchange on the development of next-gen 155mm artillery shells by the company. The stock exchange BSE had sought a clarification from Reliance Infrastructure on Wednesday about an article in Business Today, titled "Reliance Infra becomes first private Indian firm to develop next-gen 155mm artillery shells". In its response, the Anil Ambani-owned group stock said that it has a number of defence SPVs that are engaged in various businesses, including one SPV which is in the process of developing ammunition with the DRDO project of the Government of India. "The activities are routine in nature as per the objectives of the company. There were no negotiations as per our knowledge and information," the company said. Furthermore, it added that the development of ammunition by a subsidiary company is in the normal course of business and is not a disclosable event. Reliance Infra also said that as on date, there was no order from the Indian Army for ammunition under development. Meanwhile, in a major relief for Reliance Infra, National Company Law Appellate Tribunal (NCLAT) on Wednesday stayed insolvency proceedings against the company that were initiated by IDBI Trusteeship Services Ltd over an alleged default of ₹ 88 crore. The ADAG stock Reliance Infrastructure declined as much as 4.8% in intra-day trade on Thursday. It hit the day's low of ₹ 362. However, this fall is a small dent in the massive rally the Reliance Infrastructure share price has seen recently. The BSE Smallcap stock is up 17% in a week and 68% in three months. In 2025 so far, Reliance Infra share has added 15.60% while it has emerged as a multibagger stock over a year, rallying 146%. As of 3.20 pm, Reliance Infrastructure share price was at ₹ 373.80, down 1.75%. Disclaimer: This story is for educational purposes only. The views and recommendations made above are those of individual analysts or broking companies, and not of Mint. We advise investors to check with certified experts before making any investment decisions.
Mint
13 minutes ago
- Mint
Dassault Aviation partners with Tata to manufacture first-ever Rafale fighter aircraft fuselage in India
Dassault Aviation and Tata Advanced Systems Limited have signed four Production Transfer Agreements to manufacture the Rafale fighter aircraft fuselage in India, marking a significant step forward in strengthening the country's aerospace manufacturing capabilities and supporting global supply chains. This facility represents a significant investment in India's aerospace infrastructure and will serve as a critical hub for high-precision manufacturing. Under the scope of the partnership, Tata Advanced Systems will set up a cutting-edge production facility in Hyderabad for the manufacture of key structural sections of the Rafale, including the lateral shells of the rear fuselage, the complete rear section, the central fuselage, and the front section. The first fuselage sections are expected to roll off the assembly line in FY2028, with the facility expected to deliver up to two complete fuselages per month. 'For the first time, Rafale fuselages will be produced outside France. This is a decisive step in strengthening our supply chain in India. Thanks to the expansion of our local partners, including TASL, one of the major players in the Indian aerospace industry, this supply chain will contribute to the successful ramp-up of the Rafale, and, with our support, will meet our quality and competitiveness requirements', said Eric Trappier, Chairman and CEO of Dassault Aviation. This partnership aims to strengthen India's position as a key player in the global aerospace supply chain while supporting its goal of greater economic self-reliance. Tata Advanced Systems Limited, a wholly owned subsidiary of Tata Sons, is a significant player for aerospace and defence solutions in India. It offers a full range of integrated solutions across: Aerostructures, Aeroengines, Airborne Platforms Systems, Defence & Security, and land Mobility. Sukaran Singh, Chief Executive Officer and Managing Director, Tata Advanced Systems Limited, said, 'This partnership marks a significant step in India's aerospace journey. The production of the complete Rafale fuselage in India underscores the deepening trust in Tata Advanced Systems' capabilities and the strength of our collaboration with Dassault Aviation. It also reflects the remarkable progress India has made in establishing a modern, robust aerospace manufacturing ecosystem that can support global platforms.'
Time of India
15 minutes ago
- Time of India
Rahul Gandhi cites fall in vehicle, mobile sales to criticise govt's ‘event-driven' politics
Congress leader Rahul Gandhi on Thursday cited the drop in the sales of two-wheelers and cars as well as the fall in the mobile market to attack the government and said the country needs politics that is not about the glitz of events but connected with the reality of everyday life. The Leader of Opposition in the Lok Sabha asserted that the country needs an economy that works for every Indian, not just for a select few capitalists. "The statistics tell the truth. In the last year, two-wheeler sales have fallen by 17 per cent and car sales by 8.6 per cent. The mobile market has fallen by 7 per cent. On the other hand, both expenses and debt are constantly increasing: house rent, domestic inflation, education expenses, almost everything is becoming expensive," Gandhi said in his post in Hindi on X. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Giao dịch CFD với công nghệ và tốc độ tốt hơn IC Markets Đăng ký Undo — RahulGandhi (@RahulGandhi) These are not just figures, but the reality of the economic pressure under which every common Indian is suffering, he said. Live Events "We need politics that is not about the glitz of events, but connected with the reality of everyday life - that asks the right questions, understands the situation and responds responsibly. We need an economy that works for every Indian, not just for a select few capitalists," Gandhi said. The Congress has been attacking the government over its handling of the economy, alleging that issues like rising prices , decreasing private investment, and stagnating wages are hurting common people.
